Breath test may spot COPD patients at risk for Flare-Ups

NCT ID NCT07396311

Not yet recruiting Knowledge-focused Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 120 adults with COPD who are starting triple inhaler therapy as part of their routine care. Researchers will measure a breath biomarker called FeNO at the start to see if it predicts future flare-ups or lung function decline. The goal is to better understand which patients are at higher risk, but no new treatment is being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which COPD patients are at higher risk for flare-ups, allowing more personalized monitoring or treatment adjustments.
What could go wrong: This is an observational study, not a treatment trial. It only looks for a link between FeNO levels and flare-ups; it won't prove that changing therapy based on FeNO improves outcomes. Results may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Chang Gung Medical Foundation

Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.